Location History:
- Hockessin, DE (US) (2004)
- Yardley, PA (US) (2008 - 2024)
- Hopewell, NJ (US) (2022 - 2024)
Company Filing History:
23 out of 3,684 
7 out of 183 
Years Active: 2004-2024
Title: **Eldon Scott Priestley: Innovator in Pharmaceutical Chemistry**
Introduction
Eldon Scott Priestley is a prominent inventor based in Yardley, PA, known for his significant contributions to pharmaceutical chemistry. With a remarkable portfolio of 23 patents, Priestley has established himself as a key figure in the development of novel therapeutic compounds aimed at treating various medical conditions.
Latest Patents
Among his latest patents is an innovative approach to inhibiting platelet aggregation. One patent focuses on imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors. This invention details thiazole compounds designed to serve as effective medicaments for preventing thromboembolic disorders. Additionally, he has developed bicyclic heteroaryl substituted compounds, which include methods of usage as PAR4 inhibitors. These compounds are poised to play an essential role in treating thromboembolic disorders or providing primary prophylaxis against them.
Career Highlights
Priestley’s career features prominent affiliations with leading organizations in the pharmaceutical sector. Notably, he has worked with Bristol-Myers Squibb Company, where he contributed to the development of groundbreaking medical technologies. His time at universities also showcases his commitment to research and innovation, including his association with Université de Montréal.
Collaborations
Collaboration has been a cornerstone of Priestley's career. He has worked alongside esteemed colleagues such as Xiaojun Zhang and Jeremy M. Richter. Their combined expertise has fostered advancements in the understanding and application of compounds targeting platelet aggregation.
Conclusion
Eldon Scott Priestley’s contributions to pharmaceutical innovations demonstrate the vital role of inventors in advancing medical science. With his extensive patent portfolio, he continues to pave the way for new treatments that can significantly impact patient care, particularly in the management of thromboembolic disorders.